Pfizer Inc. (NYSE:PFE) Shares Bought by Steigerwald Gordon & Koch Inc.

Steigerwald Gordon & Koch Inc. grew its position in Pfizer Inc. (NYSE:PFE - Free Report) by 10.2% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 504,224 shares of the biopharmaceutical company's stock after acquiring an additional 46,760 shares during the quarter. Steigerwald Gordon & Koch Inc.'s holdings in Pfizer were worth $13,377,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. State Street Corp grew its stake in shares of Pfizer by 1.2% in the 3rd quarter. State Street Corp now owns 290,460,600 shares of the biopharmaceutical company's stock valued at $8,405,930,000 after purchasing an additional 3,405,539 shares during the last quarter. Charles Schwab Investment Management Inc. increased its stake in Pfizer by 11.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 130,143,942 shares of the biopharmaceutical company's stock valued at $3,766,366,000 after buying an additional 12,864,343 shares during the period. Geode Capital Management LLC lifted its stake in shares of Pfizer by 1.6% in the 3rd quarter. Geode Capital Management LLC now owns 117,666,245 shares of the biopharmaceutical company's stock worth $3,392,342,000 after acquiring an additional 1,855,419 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Pfizer by 22.4% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 38,068,879 shares of the biopharmaceutical company's stock worth $1,101,713,000 after acquiring an additional 6,977,587 shares during the period. Finally, Swiss National Bank boosted its holdings in Pfizer by 0.6% in the 3rd quarter. Swiss National Bank now owns 16,819,712 shares of the biopharmaceutical company's stock valued at $486,762,000 after purchasing an additional 100,900 shares in the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Pfizer

In other Pfizer news, Director Scott Gottlieb acquired 1,000 shares of the company's stock in a transaction dated Wednesday, October 30th. The stock was bought at an average price of $28.24 per share, with a total value of $28,240.00. Following the completion of the transaction, the director now directly owns 10,000 shares of the company's stock, valued at approximately $282,400. The trade was a 11.11 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 0.06% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of research analysts recently weighed in on PFE shares. Evercore ISI raised Pfizer to a "strong-buy" rating in a report on Wednesday, October 30th. Sanford C. Bernstein started coverage on shares of Pfizer in a research note on Thursday, October 17th. They issued a "market perform" rating and a $32.00 price objective on the stock. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $45.00 price target on shares of Pfizer in a report on Wednesday, October 23rd. Wolfe Research began coverage on shares of Pfizer in a research note on Friday, November 15th. They set an "underperform" rating and a $25.00 price objective for the company. Finally, Truist Financial lowered their target price on Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a report on Wednesday, December 18th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, Pfizer has an average rating of "Moderate Buy" and an average target price of $32.00.

Pfizer Trading Down 0.7 %

NYSE PFE traded down $0.19 during trading hours on Friday, hitting $26.30. 35,146,711 shares of the company's stock were exchanged, compared to its average volume of 35,869,448. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The firm has a market capitalization of $149.06 billion, a P/E ratio of 35.55, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64. The business's 50 day moving average is $26.08 and its 200-day moving average is $27.99. Pfizer Inc. has a 12-month low of $24.48 and a 12-month high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The business had revenue of $17.70 billion for the quarter, compared to analysts' expectations of $14.92 billion. During the same period last year, the company earned ($0.17) earnings per share. The company's quarterly revenue was up 31.2% on a year-over-year basis. As a group, analysts anticipate that Pfizer Inc. will post 2.94 EPS for the current fiscal year.

Pfizer Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be given a $0.43 dividend. This is a positive change from Pfizer's previous quarterly dividend of $0.42. This represents a $1.72 annualized dividend and a dividend yield of 6.54%. The ex-dividend date of this dividend is Friday, January 24th. Pfizer's dividend payout ratio (DPR) is 232.43%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.